AI Generated Image
The US Just Approved Its First mRNA Flu Vaccine. Is This a New Era?
ZME Science • • general
Key Points:
- The FDA has approved Moderna’s mFlusiva, the first mRNA flu vaccine in the U.S., for adults aged 50 and older, with traditional approval for ages 50-64 and accelerated approval for those 65 and older pending further evidence.
- In a large trial, mFlusiva outperformed a standard-dose flu vaccine, showing a 26.6% relative reduction in influenza illness and a 47.9% reduction in serious cases, demonstrating the potential advantages of mRNA technology for flu prevention.
- mRNA vaccines offer faster and more adaptable production compared to traditional egg-based methods, potentially reducing the risk of strain mismatch and improving vaccine effectiveness against rapidly evolving influenza viruses.
- This approval marks a significant step toward improving annual flu vaccination strategies and may pave the way for future combination vaccines protecting against both influenza and COVID-19.
- While broad commercial availability may take time due to pre-arranged vaccine purchasing cycles, mFlusiva represents a promising advancement in flu vaccine technology with the potential to save lives and reduce disease burden annually.
